Release No 8/2010
Affitech Signs Strategic Alliance
with Russian Biotech Partner

NauchTekhStroy Plus, (NTS Plus), a newly formed joint venture subsidiary of
Pharmstandard, Russia's leading domestic pharmaceutical company and a
participant in the leading Russian biotech project ?Generium', will conduct
clinical development and registration of two innovative Affitech antibodies for
Russian and CIS markets

- NTS Plus will pay ?23 million in fees and advanced royalties to Affitech

- Pharmstandard will commercialise these antibody products in Russia and CIS

- Russian Investor, Trans Nova Investments, becomes majority shareholder in
Affitech by subscribing for ?20.9 million in new Affitech shares

- Affitech shares continue to trade on NASDAQ/OMX Copenhagen Stock Exchange


--------------------------------------------------------------------------------
| For more information please contact: |
--------------------------------------------------------------------------------
| |
| Affitech A/S: |
| |
| Dr Robert Burns, Chief Executive Officer, |
| Tel # +45 5590 7642 |
| Randi Krogsgaard, Corporate Communications |
| Tel # +45 2320 1001 |
| [email protected] |
| NTS Plus/Pharmstandard: |
| Krylov Igor, Chief Executive Officer, |
| Tel # +7 495 970-00-34 |
| Arkhangelskaya Elena , Chief Financial Officer, |
| Tel # +7 495 970-00-35 |
--------------------------------------------------------------------------------

affitech_signs_strategic_alliance_with_russian_biotech_partner_0810_uk.pdf